phrykt

Autolus Therapeutics plc (AUTL): who owns it and who trades it

As of Nov 16, 2026, AUTL insiders reported 1 open-market sale worth $15.7K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Cintia Piccina (U.S. CCO & Country Gen M), with $15.7K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Autolus Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns AUTL

84 funds and institutions reported AUTL shares worth $212M at the end of Q2 2026, about 50% of the company. The largest holder is Mak Capital One LLC with 12.6%.

Funds and institutions (13F) 50%Everyone else 50%

10 largest owners, by share of the company

Mak Capital One LLC12.6%
Blackstone Inc.7.7%
Syncona Portfolio Ltd6.3%
Armistice Capital, LLC5.6%
Tetragon Partners GP Ltd3.6%
Schroder Investment Management Group2.9%
Frazier Life Sciences Management, L.P.1.7%
BNP PARIBAS ASSET MANAGEMENT Holding S.A.1.3%
Laurion Capital Management LP1.2%
Renaissance Technologies LLC0.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Mak Capital One LLC33.62M12.63%$53.8MNo change
Blackstone Inc.20.49M7.70%$32.8MNo change
Syncona Portfolio Ltd16.64M6.25%$26.6MNo change
Armistice Capital, LLC15.00M5.64%$24M-5%
Tetragon Partners GP Ltd9.50M3.57%$15.2MNo change
Schroder Investment Management Group7.83M2.94%$12.9M-17%
Frazier Life Sciences Management, L.P.4.45M1.67%$7.1MNo change
BNP PARIBAS ASSET MANAGEMENT Holding S.A.3.36M1.26%$5.4MNo change
Laurion Capital Management LP3.32M1.25%$5.3MNo change
Renaissance Technologies LLC1.98M0.75%$3.2M-14%
Bank of America Corp1.61M0.60%$2.6M-13%
BlackRock, Inc.1.60M0.60%$2.6M+8%
UBS Group AG1.52M0.57%$2.4M+16%
Morgan Stanley1.26M0.47%$2M+34%
Millennium Management LLC1.22M0.46%$2M+498%
Cetera Investment Advisers1.16M0.43%$1.9M+3%
Balyasny Asset Management L.P.972,7480.37%$1.6M+0%
JPMorgan Chase & Co913,2390.34%$1.5MNew
Alphabet Inc.698,2620.26%$1.1MNo change
Citadel Advisors LLC695,8900.26%$1.1M+51%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, AUTL insiders reported $0 of open-market purchases and $15.7K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$15.7K
1 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Sep 2, 2026
Filed Sep 3, 2026

Purchases and sales by month

$15.7K$15.7KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 2, 2026Cintia PiccinaU.S. CCO & Country Gen MSale6,713$2.34$15.7KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Cintia PiccinaU.S. CCO & Country Gen Manager–$15.7KSep 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AUTL short interest

Low short interest. 3.2% of AUTL shares are sold short: about 1 share in 31. Over the last 12 reports the number of shares short went down 38%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 8.63M AUTL shares were sold short, 3.2% of the shares outstanding, down 4.8% from the report before. At the average daily volume of 1.83M shares, buying them all back would take about 4.7 trading days (days to cover).

Shares short, % of all shares

3.24%May 15Oct 306.07%

Days to cover

4.7May 15Oct 3018.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20268.63M3.24%-5%1.83M4.7
Oct 15, 20269.07M3.41%+8%1.77M5.1
Sep 30, 20268.40M3.16%+1%1.48M5.7
Sep 15, 20268.33M3.13%-8%1.72M4.8
Aug 31, 20269.08M3.41%-13%2.52M3.6
Aug 14, 202610.48M3.94%-24%4.39M2.4
Jul 31, 202613.79M5.18%-9%828,90116.6
Jul 15, 202615.14M5.69%+21%1.44M10.5
Jun 30, 202612.49M4.69%-7%942,33913.3
Jun 15, 202613.48M5.06%+5%1.32M10.2
May 29, 202612.79M4.80%-9%1.85M6.9
May 15, 202614.02M5.27%+7%1.63M8.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Autolus Therapeutics company events

Autolus Therapeutics filed 14 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, auditor, job cuts). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Aug 11, 2026ResultsReleased financial results. Filing
  3. Aug 3, 2026AnnouncementThe Company announced an increase in full year 2026 guidance for AUCATZYL® net product revenue to $140 million to $150 million, from between $120 million to $135 million. Filing
  4. Aug 3, 2026AgreementAutolus Therapeutics plc entered into a Note Purchase Agreement and Guaranty with certain subsidiaries of the Company, as guarantors, the noteholders party thereto and Perceptive Credit Holdings V, LP, as administrative agent for the noteholders (in such capacity, together with permitted successors… Filing
  5. Jun 29, 2026VoteReported shareholder vote results. Filing
  6. Jun 9, 2026AnnouncementAutolus Therapeutics plc published its UK Annual Report and Accounts for the year ended December 31, 2025 and distributed a notice of its annual general meeting to be held on June 29, 2026, a form of proxy and its UK Annual Report to its ordinary shareholders. Filing
  7. May 14, 2026ResultsReleased financial results. Filing
  8. Apr 29, 2026Job cutsAnnounced job cuts or other exit costs. Filing
  9. Apr 16, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
  10. Apr 8, 2026AnnouncementShared information with investors. Filing
  11. Mar 27, 2026ResultsReleased financial results. Filing
  12. Jan 26, 2026AgreementAutolus Limited, a wholly owned subsidiary of Autolus Therapeutics plc (the “ registrant ”, and together with Autolus Limited, the “ Company ”), entered into a Master Service Agreement with AGC Biologics S.p.A for the manufacture and supply of lentiviral vector, a raw material which is critical for… Filing
  13. Jan 12, 2026AnnouncementThe Company announced preliminary unaudited AUCATZYL net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025. Filing
  14. Dec 2, 2025LeadershipAutolus Therapeutics plc announced that its board of directors, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Ryan Richardson to serve as a Class I director of the Company, effective December 1, 2025 and continuing until the Company’s 2028… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Autolus Therapeutics financials

Famous investors that hold AUTL

4 of the 50 well-known investors we track reported holding AUTL in their latest 13F filing. The largest position is Jim Simons's, worth $4.8M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20262.49M$4.8M0.0%+26%
Israel Englander · Millennium ManagementQ3 20262.16M$4.2M0.0%+77%
Ken Griffin · Citadel AdvisorsQ3 20261.63M$3.2M0.0%+134%
Steve Cohen · Point72 Asset ManagementQ3 2026134,420$261K0.0%+89%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named AUTL in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Armistice Capital, LLC13G/A5.2%
Nov 16, 2026MAK Capital Fund LP13G/A11.5%
Nov 16, 2026Armistice Capital, LLC13G/A5.2%
Nov 16, 2026MAK Capital Fund LP13G/A11.5%
Nov 12, 2026Qatar Investment Authority13G/A3.5%
Nov 12, 2026Qatar Investment Authority13G/A3.5%
Nov 10, 2026BXLS V - Autobahn L.P.13D/A7.6%
Nov 10, 2026BXLS V - Autobahn L.P.13D/A7.6%

Questions about Autolus Therapeutics plc (AUTL) stock

Who owns the most AUTL stock?

The largest reported owner of Autolus Therapeutics plc (AUTL) is Mak Capital One LLC, with 12.6% of the company. In total, 84 funds and institutions reported holding AUTL at the end of Q2 2026, together about 50% of the shares. See the largest owners.

Are AUTL insiders buying or selling?

In the last 12 months, AUTL insiders reported no open-market purchases and 1 sale worth $15.7K. The latest trade was on Sep 2, 2026. See every trade.

What is the short interest in AUTL?

As of Oct 30, 2026, 8.63M AUTL shares were sold short, 3.2% of the shares outstanding, down 4.8% from the report before. At the average daily volume of 1.83M shares, buying them all back would take about 4.7 trading days (days to cover). See the history.

Which famous investors hold AUTL?

4 of the 50 well-known investors we track reported AUTL in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $4.8M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.